L.A. Pardo, D. Gomez-Varela, F. Major, K. Sansuk, R. Leurs, B.R. Downie, L.F. Tietze and W. Stuhmer Pages 675 - 682 ( 8 )
Kv10.1 has recently become generally accepted as a promising cancer target, as it is ectopically expressed in the majority of solid tumors. Due to its cell-surface accessibility, Kv10.1 has a strong potential for tumor treatment and diagnosis. Given that its mode of action is likely independent of conventional cancer pathways such as tyrosine kinases, KV10.1 opens a novel window for treating cancer. In this review we will give an overview of the current status of data linking Kv10.1 to cancer, and propose techniques that could exploit Kv10.1s properties for the management of cancer
ADEPT,astemizole,cancer diagnosis,cancer prognosis,eag1,ether a go-go,imipramine,immunotherapy,immunotargeted therapy,KCNH1,KV10.1,potassium channel,tumor therapy
, , , , , , , Max-Planck-Institute of Experimental Medicine, Hermann-Rein-Str. 3, 37075 Gottingen, Germany.